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Objective. Advanced glycation end products (AGEs) are important in the pathophysiology of type 2 diabetes mellitus (T2DM).
They directly cause insulin secretory defects in animal and cell culture models and may promote insulin resistance in
nondiabetic subjects. We have developed a highly sensitive liquid chromatography-tandem mass spectrometry method for
measuring AGEs in human serum. Here, we use this method to investigate the relationship between AGEs and insulin secretion
and resistance in patients with T2DM. Methods. Our study involved 15 participants with T2DM not on medication and 20
nondiabetic healthy participants. We measured the AGE carboxyethyllysine (CEL), carboxymethyllysine (CML), and methyl-
glyoxal-hydro-imidazolone (MG-H1). Plasma glucose and insulin were measured in these participants during a meal tolerance
test, and the glucose disposal rate was measured during a euglycemic-hyperinsulinemic clamp. Results. CML and CEL levels
were significantly higher in T2DM than non-DM participants. CML showed a significant negative correlation with insulin
secretion, HOMA-%B, and a significant positive correlation with the insulin sensitivity index in T2DM participants. There was
no correlation between any of the AGEs measured and glucose disposal rate. Conclusions. These results suggest that AGE might
play a role in the development or prediction of insulin secretory defects in type 2 diabetes.
1. Introduction
Type 2 diabetes mellitus is a heterogeneous disease character-
ized by insulin resistance and defective insulin secretion [1].
Advanced glycation end products (AGEs) are produced by
a nonenzymatic reaction between amino and carbonyl
groups [2]. This reaction, called the Maillard or amino-
carbonyl reaction, is accelerated in the state of hyperglycemia
in diabetes. AGEs have been reported to be correlated with
the progression of diabetes and aging [3]. An animal study
demonstrated that exposure to excess AGEs activates path-
ways of β-cell damage which, via mitochondrial superoxide
generation, can impair insulin secretion [4]. A human study
also showed a cross-sectional association between AGEs
and acute insulin secretion during glucose tolerance testing
in healthy humans [5]. Another human study demonstrated
that the circulating level of AGEs is associated with insulin
resistance as evaluated by the homeostasis model assessment
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for insulin resistance (HOMA-IR), even in nonobese, nondi-
abetic subjects [6]. These results suggest that AGEs may
affect insulin secretion as well as insulin resistance. However,
there are few studies on the relationship between AGEs and
insulin secretion ability or insulin resistance in patients with
type 2 diabetes. Moreover, the most precise method for asses-
sing insulin resistance is the glucose clamp technique, but
this method is very complicated [7]. Instead, the HOMA-IR
index is widely used in clinical practice and in clinical studies
[8]. However, the validity of HOMA-IR may be limited in
some patients, particularly those with a low BMI, reduced
β-cell function, and high fasting glucose levels [9]. Since
Asian and Japanese patients often show reduced β-cell func-
tion [10], a clamp study is required for evaluating insulin
resistance in these populations.
Nε-(carboxymethyl)lysine (CML), Nε-(carboxyethyl)ly-
sine (CEL), glyoxal-derived hydroimidazolone (G-H1), and
methylglyoxal-derived hydroimidazolone (MG-H1) are
known as representative AGEs generated in vivo [2]. Some
AGEs such as CML are formed by an oxidative process and
are called glycoxidation products. Several methods have been
developed to determine the AGE content in biological sam-
ples. CEL, CML, and pentosidine have been measured using
an immunological method with antibodies like rabbit-anti-
CML-IgG and D12 antibody for CML [2]. Although ELISA
is rapid, specific antibodies for each compound are required,
the results are expressed in arbitrary units instead of actual
concentrations, and the sample matrix, which can lead to
incorrect estimation of AGE levels, affects the specificity of
the assay significantly [11]. Recently, we developed a method
for the simultaneous quantitation of several AGEs in brown-
colored food using liquid chromatography-tandem mass
spectrometry without ion-pair reagents and derivatization
(LC-MS/MS method) [2]. We also developed a method for
the simultaneous quantitation of several AGEs in human
serum using LC-MS/MS method in this study.
According to past reports, there were some reports about
the relationship between AGEs and insulin secretion and
insulin resistance in the human healthy subjects; however,
there were few reports about type 2 DM subjects. Further-
more, there were some reports about the relationship
between AGEs and insulin secretion and insulin resistance
by using the ELISA method; however, there were few reports
about the exact quantitation of AGEs by using LC-MS/MS
methods. Therefore, the aim of this study is to investigate
the relationship between AGEs and insulin secretion and
insulin resistance in the type 2 DM subjects by using LC-
MS/MS methods. Based on previous studies, we hypothe-
sized that patients with type 2 diabetes mellitus would show
a correlation between AGE content and both insulin secre-
tion ability and insulin resistance. In this study, we per-
formed a meal tolerance test (MTT) and a glucose clamp in
Japanese patients with type 2 diabetes mellitus and nondia-
betic healthy volunteers and measured serum AGEs by the
LC-MS/MS method.
2. Research Design and Methods
2.1. Subjects. Nine males and six females with type 2 diabetes
mellitus (T2DM participants) participated in this study at
Tottori University Hospital between 2014 and 2016. Type 2
diabetes mellitus was diagnosed using the criteria of the
World Health Organization [12]. Patients with pancreatic
disease, liver disease, or renal failure or those taking diabeto-
genic medications such as corticosteroids were excluded
from this study. All T2DM participants were on diet therapy
alone. Twelve male and eight female nondiabetic healthy vol-
unteers (non-DM participants) were also recruited for this
study. None of the non-DM participants had type 2 diabetes
mellitus or were taking diabetic medications. Participant
characteristics from the T2DM and non-DM groups are
given in Table 1. The mean age, BMI, waist circumstance,
Table 1: Participant characteristics.
T2DM Non-DM P value
n 15 20
Sex (male/female) 9/6 12/8
Age (years) 56.1± 12.0 33.9± 9.5 <0.001
BMI (kg/m2) 27.46± 4.1 21.8± 2.9 <0.001
Waist circumference (cm) 95.7± 12.3 77.2± 9.9 <0.001
Fasting plasma glucose (mmol/L) 6.83± 0.75 4.80± 0.43 <0.001
HbA1c (%) 7.33± 0.83 5.33± 0.27 <0.001
HbA1c (mmol/mol) (56.6) (35.0)
Insulinogenic index (IGI) 0.83± 1.07 1.44± 1.34 0.14
IRI-AUC 861.8± 429.2 616.3± 293.7 0.07
HOMA-%B (%) 73.7± 37.9 124.1± 68.8 <0.05
HOMA-IR 3.94± 2.50 1.70± 1.13 <0.001
Insulin sensitivity index (ISI) 4.11± 3.16 7.31± 3.32 <0.001
GDR 5.44± 2.34 9.52± 2.61 <0.001
Data are mean ± standard deviation. GDR: glucose disposal rate; HOMA-%B: homeostasis model assessment of beta cell function; HOMA-IR: homeostasis
model assessment for insulin resistance; IRI-AUC: immunoreactive insulin area under the curve; Non-DM: nondiabetic study participants; T2DM: study
participants with type 2 diabetes mellitus.
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fasting plasma glucose (FPG), HbA1c, and HOMA-IR of the
DM group were significantly higher than those of the non-
DM group, and the mean insulin sensitivity index (ISI) and
glucose disposal rate (GDR) of the DM group were signifi-
cantly lower than those of the non-DM group. There was
no significant difference in insulin AUC and insulinogenic
index (IGI) between the DM group and non-DM group. All
participants were examined using the protocols reported in
our previous study [13].
This study was approved by the Ethics Committee of the
Faculty of Medicine, Tottori University (approval number
G161). Informed consent was obtained from all of the partic-
ipants using a procedure approved by the Ethics Committee.
2.2. Meal Tolerance Test. After fasting for at least 12 h, partic-
ipants visited the clinic in the morning and consumed a test
meal prepared by the Japan Diabetes Society (460 kcal/
1882 kJ; 15% protein, 35% fat, and 50% carbohydrate; 1.6 g
salt) [14]. Plasma glucose and insulin were measured at 0
(fasting), 30, 60, 120, and 180min after the test meal.
Plasma glucose was measured using the glucose oxidase
method. Plasma insulin levels were measured using chemi-
luminescent immunoassays. Plasma insulin was defined as
immunoreactive insulin (IRI). HbA1c was measured by
high-performance liquid chromatography. HbA1c percent-
age values were converted to International Federation of
Clinical Chemistry values (mmol/mol) using the HbA1c
converter developed by the National Institutes of Diabetes
and Digestive and Kidney Diseases [15].
2.3. Euglycemic-Hyperinsulinemic Clamp. Glucose clamps
were performed 2 days after the MTT. We examined the
participants in the morning after an overnight fast. We can-
nulated an antecubital vein to administer the infusate, and
we also cannulated a dorsal vein and kept warm to facilitate
venous sampling and provide arterialized venous blood. We
performed the euglycemic-hyperinsulinemic clamp to deter-
mine insulin sensitivity in the peripheral tissues by using an
artificial endocrine pancreas (STG 55; Nikkiso, Shizuoka,
Japan) [7]. We used a primed constant infusion of insulin
(100mU/m2/min) and computer-controlled exogenous infu-
sion of a glucose solution to achieve steady-state plasma insu-
lin levels and maintain plasma glucose levels at 5.2mmol/L
(95mg/dL). The previous studies reported that the steady-
state plasma insulin level was 1200 pmol/L in patients with
type 2 diabetes mellitus, by using this insulin infusion proto-
col [16, 17]. We calculated the steady-state glucose infusion
rate between 90 and 120min, and we defined the mean
glucose infusion rate during this time as GDR (glucose dis-
posal rate), which was used as a marker of peripheral insulin
sensitivity. The glucose clamp method is a well-established
procedure at our hospital [13, 18].
In a previous report, a GDR> 10.0mg⋅kg−1⋅min−1 at an
insulin infusion rate of 100mU/m2/min was considered
normal [19], and a GDR< 5.0mg⋅kg−1⋅min−1 was considered
to be obviously insulin resistant [20].
2.4. Calculation of Insulin Resistance and Secretion Indexes.
HOMA-IR [8] = [fasting plasma glucose (mmol/L)]×
[fasting plasma insulin (pmol/L)]/135. The normal range
for HOMA-IR is <2.5 [21].
HOMA-%B (homeostasis model assessment of beta
cell function) [8] = {20× [fasting plasma insulin (pmol/L)]}/
{[fasting plasma glucose (mmol/L)]− 3.5} (%).
Insulin sensitivity index (ISI) [22] = 10,000/√{[fasting
plasma glucose (mmol/L)× fasting plasma insulin (pmol/L)]×
[mean glucose×mean insulin during the MTT]}. The
normal range for ISI is >2.5 [23].
Insulinogenic index (IGI) [24] = {[insulin (pmol/L) at
30min]− [insulin (pmol/L) at 0min]}/{[glucose (mmol/L)
at 30min]− [glucose (mmol/L) at 0min]}.
2.5. Measurement of AGEs [2]
2.5.1. Chemicals and Reagents. Standards CML, CEL, and
MG-H1 and internal standards CML-d4, CEL-d4, and MG-
H1-d3 were purchased from PolyPeptide Group (Strasbourg,
France). All other reagents were of the highest grade available
and were purchased from Wako (Osaka, Japan).
Each stock solution of CML, CEL, and MG-H1 at
0.1mg/mL was prepared in purified water and stored
at −20°C. Stock solutions of internal standards CML-d4,
CEL-d4, and MG-H1-d3, at 0.1mg/mL, were prepared
in the same manner. Before analysis, we prepared work-
ing standard solutions (final concentrations 0–20 ng/mL)
and internal standard working solutions (final concentra-
tion 10 ng/mL) by diluting the stock solutions using 1%
aqueous formic acid.
2.5.2. Instruments. High-performance liquid chromatogra-
phy experiments were performed on a prominence series
liquid chromatograph system (Shimadzu, Kyoto, Japan)
consisting of a binary pump, in-line degasser, autosampler,
and column oven. Chromatographic separation was achieved
with an Intrada Amino Acid column (2.0mm I.D.× 150mm,
Imtakt Co. Ltd., Kyoto, Japan) at 40°C with an injection
volume of 10μL. The mobile phase consisted of solvent A,
containing 100mM ammonium formate in water, and
solvent B, containing 0.5% formic acid in acetonitrile. The
separation conditions were a linear gradient from 75 to
50% of solvent B from 0 to 7min, from 50 to 0% of solvent
B from 7 to 9min, and 0% of solvent B from 9 to 20min.
The flow rate was 0.3mL/min. The column was equilibrated
for 6min under the initial conditions before each injection.
An AB Sciex QTRAP 5500 mass spectrometer (AB
SCIEX, Tokyo, Japan) equipped with an electrospray ion
source in the positive ion mode was used under the
following operating conditions: curtain gas 10 psi; ion
spray voltage 5000V; temperature of ion source 700°C;
ion source gas 1 50 psi; ion source gas 2 70 psi; collision
gas 8.0 psi; and entrance potential 10V. Seven glycation
free adducts were detected individually in the postcolumn
by MS/MS with multiple reaction monitoring (MRM) for
transition of the parent ions to the product ions. LC-MS/
MS data were acquired and processed using Analyst
version 1.5 software (Applied Biosystems/MDS Analytical
Technologies, Tokyo, Japan).
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2.5.3. Preparation of Serum Extracts. Whole blood was col-
lected into vacuum blood collection tubes containing a serum
separating agent and a procoagulant film (VENOJECT II,
Terumo Co., Tokyo, Japan) and refrigerated at 4°C. After
standing for 30min, serum was obtained by centrifugation
at 3000×g for 10min and stored at −80°C until deproteiniza-
tion. For deproteinization, an aliquot of serum (50μL) was
mixed with 6% aqueous sulfosalicylic acid (50μL) and centri-
fuged at 13000 rpm for 5min. The supernatant was trans-
ferred to a filter unit (ULTRAFREE-C3LCR, 0.2μm, Merck
Millipore, Darmstadt, Germany) and centrifuged below
12000×g for 5min. The supernatant was transferred to a
microtube and then diluted three times with 1% aqueous
formic acid, forming the serum extract.
2.5.4. Method Validation.Matrix effects of the serum extracts
were determined by preparing mixtures containing 25,
100, and 200ng/mL of each AGE in 1% aqueous formic
acid. Next, 5μL of each mixture was added to 45μL of a
serum extract or 1% aqueous formic acid. For the blank
sample (0 ng/mL), 5μL of water was added to 45μL of a
serum extract or 1% aqueous formic acid. The final con-
centrations of the AGEs were 0, 2.5, 10, and 20ng/mL.
These standard solutions dissolved in serum extracts or
1% aqueous formic acid were stored at −30°C until LC-
MS/MS analysis.
An internal standard method using isotopic AGEs was
also performed. Aliquots of the serum extracts (45μL)
were dispensed and spiked with a mixture of three internal
standards (CML-d4, CEL-d4, and MG-H1-d3) at a final
concentration of 10ng/mL (5μL) and stored at −30°C
until LC-MS/MS analysis. Calibration curves of analyte/
internal standard peak area ratio versus AGE concentra-
tion were constructed for each of the three AGEs.
Samples were prepared for a recovery test by mixing
45μL of the serum extract with 5μL of the respective stock
solutions (CEL, CML, and MG-H1; final concentration: 2.5,
10, and 20ng/mL, resp.) containing a mixture of three
internal standards (final concentration 10 ng/mL). Percent
recovery was calculated according to the formula:
Rec % = C a − C b
C c × 100, 1
where Rec is the recovery, C a is the concentration in
spiked sample, C b is the initial concentration, and C c
is the concentration of standard mixture of three AGEs.
Our methods about meal tolerance test, glucose clamp
test, and AGE measurements were already described in the
past reports [2, 13, 18].
2.5.5. Statistical Analysis. Data are expressed as mean
± standard deviation of the mean. The area under the
curve was calculated according to the trapezoidal rule. Dif-
ferences in the mean value of AGEs between T2DM and
non-DM participants were assessed using an unpaired t-
test. Correlations between parametric clinical variables
and AGEs were determined using Pearson’s correlation
analysis. Values of P < 0 05 were considered significant.
SPSS software version 24.0 (SPSS, Chicago, IL, USA) was
used for all analyses.
3. Results
When standard CML was analyzed by MS/MS with flow
injection, CML showed an intense molecular ion at m/z
205.10 [M+H]+. Therefore, product ion scanning was
conducted for the ion, and CML-specific fragment ions
at m/z 84.10 [M+H−121]+ were identified. Similarly,
MS/MS analysis was performed for CEL and MG-H1.
The identified ions (m/z 219.10 and 84.10 for CEL, m/z
229.10 and 70.10 for MG-H1) allowed selective detection
of analytes using electrospray ionization- (ESI-) MS with
MRM. All of the settings for MRM are summarized in
Table 2. Although the detailed information of the separa-
tion mode and sample preparation for the Intrada Amino
Acid column has not been released by the supplier, the
sample preparation method was suggested by the sup-
plier, and separation and quantitation were very good
for human serum samples the same as food samples
[2]. Ion enhancement was found in CEL, CML, and
MG-H1 when the serum was diluted to 6.67 times. How-
ever, it showed good sensitivity and linearity (R2> 0.97)
in the range of 0–20 ng/mL. Therefore, the concentration
of CML, CEL, and MG-H1 was calculated from the peak
area of AGE with the peak area of internal standard of
CML-d4, CEL-d4, and MG-H1-d3.
The mean values of CEL and CML were significantly
higher in T2DM participants than non-DM participants
(Table 3). MG-H1 was also higher in T2DM participants
than non-DM participants, but this difference was not statis-
tically significant.
Across all T2DM participants, there were no correla-
tions between the AGEs and HbA1c (Table 4). CML was
strongly negatively correlated with the HOMA-%B and
IRI area under the curve and showed a significant positive
correlation with ISI. However, the AGEs did not correlate
with GDR or HOMA-IR. CEL and did not correlate with
any insulin secretion or resistance indexes.
Across all non-DM participants, CML, CEL, and MG-H1
did not correlate with HbA1c or any insulin secretion or
resistance indexes (Table 4).
Table 2: Operating parameters for serum AGE measurement using
a QTRAP 5500 mass spectrometer equipped with an electrospray














CEL 5.64 219.1 84.1 111 27 6
CML 6.01 205.1 84.1 76 25 10
MG-H1 9.09 229.1 70.1 46 30 8
CEL-d4 5.65 223.1 88.1 111 27 6
CML-d4 5.99 209.1 88.1 76 25 10
MG-H1-d3 9.07 232.1 70.1 46 30 8
DP: declustering potential; CE: collision energy; CXP: collision cell exit
potential; CEL: carboxyethyllysine; CML: carboxymethyllysine; MG-H1:
methyl-glyoxal-hydro-imidazolone.
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4. Discussion
This study shows that CML and CEL levels were signifi-
cantly higher in T2DM than non-DM participants. CML
was significantly negatively correlated with insulin secretion,
HOMA-%B and IRI-AUC, and positively correlated with
ISI, but was not correlated with GDR in T2DM. A previous
study using cell culture and animal models demonstrated
that exposure to excess AGEs activates pathways of β-cell
damage, which can impair insulin secretion [4]. β-Cells
exposed to AGEs displayed acute glucose-stimulated insulin
secretory defects, mitochondrial abnormalities including
excess superoxide generation, and reduced calcium flux.
Another study suggested that AGE injections can initiate
β-cell dysfunction in vivo [25]. A recent in vitro study also
indicated that CML caused mitochondrial dysfunction and
mitophagy in β-cells and that high levels of AGEs may
induce β-cell dysfunction and impair insulin secretion abil-
ity [26]. A recent epidemiological study also showed that
increased fasting CML levels may be predictive of type 2
diabetes development [27]. These results suggest that CML
decreases insulin secretion and is important in the patho-
physiology of impaired glucose metabolism.
In our study, CML correlated with ISI, an index which is
greatly affected by insulin secretion ability. Conversely, CML
and the other AGEs did not correlate with the GDR. It may
be difficult for the findings to explain the reasons, we
consider that HOMA-IR mainly reflects the insulin resis-
tance of liver and ISI mainly reflects the insulin resistance
of muscle [28]. However, ISI is greatly affected by the insulin
secretion ability, and if the insulin secretion ability is
decreased, ISI shows low insulin resistance [29]. We
measured GDR using the glucose clamp method, which is a
precise method for assessing insulin resistance of muscle
[28]. Therefore, we consider the results that CML correlates
with ACU-IRI and ISI, but not GDR and HOMA-IR, which
means CML mainly affects insulin secretion ability rather
than insulin resistance. Thus, we suggest that CML has a
greater effect on insulin secretion ability than on insulin
resistance. A recent study reported that a diet low in AGEs
increased insulin sensitivity in healthy, overweight individ-
uals [30]. Insulin sensitivity as evaluated by the glucose
clamp method increased after a low-AGE diet and showed
a tendency to decrease after a high-AGE diet. There was no
difference in body weight or insulin secretion between these
diet groups. The authors suggested restricting dietary AGE
content as an effective strategy to decrease diabetes and
cardiovascular disease risks in overweight individuals.
Another study reported that a low-AGE diet ameliorates
insulin resistance in obese people with the metabolic syn-
drome without necessitating a major reduction in adiposity
[31]. However, these studies differ from our study in that
their subjects did not have type 2 diabetes. We suggest that
the results of animal and cell culture studies on AGE content
and diabetes [4] are likely to be more relevant to the present
study; however, further study is needed.
Our study had several limitations. The relatively small
number of participants (total 35, T2DM 15, non-DM 20)
and the difference in age and BMI between the T2DM and
non-DM groups indicate that our results require confirma-
tion with a larger study. Therefore, we decided to add “A
Brief Report” in the title. Furthermore, the DM group was
aged and obese compared to the control group; therefore,
the elevated levels of CML and CEL may be due to aging
and obesity. However, glucose clamp test is a very compli-
cated method, and it is difficult to recruit the patients with
poorly controlled diabetes without medications and older
nondiabetic participants with obesity. We are currently
conducting a larger study, the results of which we plan








T2DM (n = 15) 15.4± 6.6 21.0± 7.0 27.2± 20.7
Non-DM (n = 20) 9.8± 2.2 15.1± 4.2 17.5± 8.2
P value <0.001 <0.01 NS
Data are mean ± standard deviation. AGEs: advanced glycation end
products; CEL: carboxyethyllysine; CML: carboxymethyllysine; MG-H1:
methyl-glyoxal-hydro-imidazolone; T2DM: study participants with type
2 diabetes mellitus; Non-DM: nondiabetic study participants; NS: not
significant.
Table 4: Correlation coefficients for the associations between AGEs
and clinical parameters.
T2DM (n = 15)
Index
CEL CML MG-H1
r P r P r P
HbA1c −0.43 NS −0.10 NS −0.11 NS
IGI −0.31 NS −0.39 NS −0.30 NS
IRI-AUC −0.27 NS −0.53 <0.05 −0.20 NS
HOMA-%B −0.14 NS −0.63 <0.05 0.01 NS
HOMA-IR −0.13 NS −0.47 NS −0.04 NS
ISI 0.26 NS 0.72 <0.01 −0.04 NS
GDR 0.31 NS 0.13 NS 0.15 NS
Non-DM (n = 20)
Index
CEL CML MG-H1
r P r P r P
HbA1c −0.03 NS −0.10 NS −0.05 NS
IGI 0.14 NS 0.26 NS −0.03 NS
IRI-AUC 0.10 NS 0.24 NS −0.18 NS
HOMA-%B 0.11 NS 0.05 NS −0.29 NS
HOMA-IR 0.04 NS −0.03 NS −0.12 NS
ISI −0.12 NS −0.24 NS −0.12 NS
GDR 0.16 NS 0.12 NS 0.03 NS
Correlation coefficients were determined using Pearson’s product moment
correlation coefficient test. AGEs: advanced glycation end products; CEL:
carboxyethyllysine; CML: carboxymethyllysine; GDR: glucose disposal rate;
HOMA-%B: homeostasis model assessment of beta cell function; HOMA-
IR: homeostasis model assessment for insulin resistance; IGI: insulinogenic
index; IRI-AUC: immunoreactive insulin area under the curve; ISI: insulin
sensitivity index; MG-H1: methyl-glyoxal-hydro-imidazolone; Non-DM:
nondiabetic study participants; T2DM: study participants with type 2
diabetes mellitus; NS: not significant.
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to publish in the future. MTT was used in our study as
OGTTs are best avoided in patients with severe diabetes
because of the risk of hyperglycemia. As IGI and ISI were
developed from OGTTs, we propose that differences
between consuming a test meal and a pure glucose load
may also affect glucose and insulin levels. Despite these
limitations, we think our study contributes to our under-
standing of the pathophysiology of type 2 diabetes.
In summary, CML and CEL levels were significantly
higher in T2DM than non-DM participants. CML was
significantly negatively correlated with insulin secretion,
HOMA-%B, and IRI-AUC and positively correlated with
ISI in T2DM participants but was not correlated with
insulin resistance as evaluated by the glucose clamp
method. In conclusion, these results suggest that AGE
might play a role in the development or prediction of
insulin secretory defects in type 2 diabetes.
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